当前位置:首页 > 科技创新 >


编辑:金沙安装 来源:金沙安装 创发布时间:2021-06-01阅读67560次
  本文摘要:The first successful “gene editing” of human embryos to prevent transmission of inherited disease, announced this week, is a landmark in biotechnology. Humanity has gained the power to engineer its own evolution by making genetic changes that will be passed down through future generations.第一例为了更好地防止遗传性疾病散播而对人类胚胎进行“基因编辑”的成功试验在这周宣布,它是生物科技行业的一块里程碑式。

The first successful “gene editing” of human embryos to prevent transmission of inherited disease, announced this week, is a landmark in biotechnology. Humanity has gained the power to engineer its own evolution by making genetic changes that will be passed down through future generations.第一例为了更好地防止遗传性疾病散播而对人类胚胎进行“基因编辑”的成功试验在这周宣布,它是生物科技行业的一块里程碑式。人类获得了设计方案本身演变的能量——根据将不容易教授给后代子孙的基因变化。

Most scientists have rightly greeted the achievement, by a US-based team working with colleagues in South Korea and China, as an experimental tour de force. Using new technology called Crispr, the researchers removed a genetic mutation that causes sudden heart failure from dozens of early human embryos with impressive precision and efficiency — and without the “off-target” impact on other genes that many feared would be an unwanted side-effect of gene editing. But much more work will be needed to assess the technique’s safety before anyone plans to implant an edited embryo into a womb.大部分生物学家恰当地亲睐由一个英国精英团队在与日本和我国朋友协作下得到 的此项造就,视其为一个试验作品。科学研究工作人员运用基因编辑技术性CRISPR,以让人印像深刻的印象的精准度和高效率,从几十个初期环节人类胚胎中手术治疗了将不容易导致突发心血管脑中风的基因突然变化,并且没对别的基因造成 “脱靶”损伤,而很多人曾一度忧虑这类损伤将是基因编辑的一种并不是非的不良反应。可是,在所有人方案将编写好的胚胎植入孑宫以前,还务必进行很多工作中,以评定这类基因编辑技术性的安全系数。

The project’s success should inspire governments, regulatory authorities and medical academies around the world to prepare more actively for clinical trials leading to genetically engineered babies. On top of thorough safety testing, extensive regulatory and ethical work with maximum public involvement will be needed before this can happen — building on the activities of bodies, such as the Nuffield Council on Bioethics in the UK and American Society of Human Genetics, that are already engaging with the subject.这一新项目的成功理应鼓励世界各地政府部门、管控组织和医科大学更为全力地准备最终将不容易带来“基因工程项目宝宝”的临床研究。在临床研究能够起动以前,除开等级森严的安全测试之外,还务必广泛的管控和伦理道德科学研究,而且让群众最大限度地参予争辩——以早就在科学研究这一主题风格的组织,如美国纳芒特微生物社会学联合会(Nuffield Council on Bioethics)和英国人类细胞生物学不容易(American Society of Human Genetics)的工作中为基本。

If we dismiss the idea of an absolute religious or philosophical prohibition of any tampering with human evolution, even to prevent the most horrible diseases, then there are several other issues to consider.如果我们拒不接受以宗教信仰或社会学为本的意味著限令对人类演变未作一切仿冒(就算为了更好地预防最恐怖的病症也没法特别注意)的意识,那麼也有别的好多个议案务必充分考虑。The “slippery slope” argument — that technology developed for good medical reasons will inevitably be applied for ethically more dubious purposes such as producing “designer babies” with enhanced looks, athletic ability or intelligence — justifies strong regulatory controls to prevent such abuse, but is surely no reason to abandon research that aims to reduce human suffering.“山体滑坡”论点论据——出自于不错医药学原因而产品研发的技术性,将难以避免的被运用于在伦理道德上更为猜疑的目地,比如生产制造具有加强表面、健身运动工作能力或智商的“室内设计师小宝宝”——表述务必强大的管控操控来防止这类诈骗,但这认可并不是撤出目地提升人类痛楚的科学研究的原因。


In fact there are sound scientific reasons why it would be extremely hard to apply the technology to genetic enhancement. One is that the desired traits depend on many genes acting together, most of them unknown; these will lie far beyond the scope of DNA editing for the foreseeable future. Another is that the experiment published this week worked well because each embryo carrying a defective heart gene also had a healthy copy, which acted as a template for the DNA repair process. This should make Crispr editing possible in thousands of other inherited disorders in which sufferers have one good and one bad copy of the gene responsible. There would be no comparable template for genetic enhancement.实际上,有充份的科学研究原因表述,为何将此项关键技术于基因加强是极其艰辛的。在其中一个缘故是,想的特点不尽相同很多基因的协同具有,在其中大部分是不知道的的;在可意识到的将来,这种将比较之下远远超过DNA编写的范围。另一个缘故是,这周公布发布的试验往往进行取得成功,是由于每一个装车有缺陷心血管基因的胚胎都是有一个身体健康的“团本”,后面一种可做为DNA修复全过程的模版。



Critics also question the need for gene editing when pre-implantation diagnosis (PGD), which selects healthy IVF embryos by a DNA test, can do the job, too. This is often true, but sometimes no healthy embryos are available — and, even when they are, gene editing could increase the number available to implant in the womb.当胚胎植入前细胞生物学临床医学(PGD)——根据DNA检测来随意选择身体健康的试管婴儿(IVF)胚胎——还可以超出某种意义目地时,批判者还指责基因编辑的重要性。这一出题通常是精确的,但有时候没身体健康的胚胎可用——再聊即便不会有身体健康的胚胎,基因编辑还可以降低可植入孑宫内的胚胎总数。

A more practical barrier to embryonic gene editing may be cost and complexity. The Crispr procedure is bound to be expensive, even after streamlining for clinical use, and PGD will still be needed before implantation to ensure that the DNA has been repaired. The number of beneficiaries may be small in the early years, but the technology’s long-term promise is so great that society must develop a framework for its clinical development. Producing healthy babies is a laudable aim.胚胎基因编辑的更为具体阻碍有可能是成本费和多元性。CRISPR手术治疗认可是划算的,即便在历经精减作为临床医学以后也不会这般,另外在植入胚胎前仍然务必PGD临床医学,以确保DNA已被整修。既得利益者的总数在前期有可能非常少,但这类技术性的长时间市场前景是这般之大,社会发展必不可少为其临床医学产品研发制定一个架构。






Copyright © 2010-2014 上海市金沙安装有限公司 版权所有  沪ICP备51051002号-8